The state of Florida currently has 52 active clinical trials seeking participants for Healthy research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
How Does the Type of Waveform Affect Tolerability With Transcutaneous Auricular Vagus Nerve Stimulation?
Recruiting
The purpose of this research study is to investigate the effects of different forms of a gentle form of electrical stimulation applied to the ear, known as transcutaneous auricular vagus nerve stimulation (taVNS). The research team is interested in how the different forms affect comfort and tolerability, as well as how well it works.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/29/2025
Locations: University of Miami, Plumer Building, Coral Gables, Florida
Conditions: Healthy
A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
Recruiting
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Clinical Pharmacology of Miami ( Site 0002), Miami, Florida
Conditions: Hepatic Impairment, Healthy Participants
A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
Recruiting
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later. A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other t... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/28/2025
Locations: Research Centers of America ( Hollywood ) ( Site 0001), Hollywood, Florida
Conditions: Healthy
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
Recruiting
The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy participants with normal liver function. The study will also assess the safety and tolerability of the single dose of palovarotene. Participants will be enrolled in stages and divided into three groups based on their liver function: * Group 1: Healthy participants with... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/27/2025
Locations: ERG - Clinical Pharmacology of Miami, Miami, Florida +1 locations
Conditions: Hepatic Impairment, Healthy
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Recruiting
To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/27/2025
Locations: Atea Study Site, Orlando, Florida +1 locations
Conditions: Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Recruiting
This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body wei... Read More
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
05/25/2025
Locations: Fortrea Clinical Research Unit, Daytona Beach, Florida +1 locations
Conditions: Healthy, Obesity
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
Recruiting
The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants. The study will last up to approximately 9 weeks, exclu... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/23/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida +1 locations
Conditions: Liver Dysfunction, Healthy
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
Recruiting
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/23/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Healthy Participants
A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)
Recruiting
The goal of the study is to learn what happens to different forms of sotatercept medications in a healthy person's body over time. Researchers want to know if there is a difference in the healthy person's body when different forms of sotatercept medications are given.
Gender:
FEMALE
Ages:
Between 18 years and 85 years
Trial Updated:
05/23/2025
Locations: Advanced Pharma CR, LLC ( Site 0005), Miami, Florida +1 locations
Conditions: Healthy
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants
Recruiting
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/23/2025
Locations: Cpmi /Id# 274464, Miami, Florida
Conditions: Healthy Volunteer
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Recruiting
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/23/2025
Locations: Fortrea Clinical Research Unit, Daytona Beach, Florida
Conditions: Healthy, Overweight, Obesity, Type 2 Diabetes
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
Recruiting
The purposes of this study are to determine: * The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body breaks down the study drug) in participants with moderate or severe liver function impairment compared to participants with normal liver function (also known as a healthy volunteer). Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/21/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida +1 locations
Conditions: Healthy, Hepatic Impairment